MiNK Therapeutics Appoints New Principal Financial and Accounting Officers

MiNK Therapeutics ( (INKT) ) has issued an announcement.

On March 13, 2026, MiNK Therapeutics appointed Melissa Orilall, currently Vice President of Global Financial Operations at Agenus Inc., as its Principal Financial Officer, formalizing her oversight of general accounting, close procedures, and financial planning and analysis for MiNK under an existing intercompany services agreement. Orilall, a Canadian CPA with prior experience at the Whitehead Institute and in corporate banking, will not receive direct compensation from MiNK, and the company disclosed that her designation involves no new arrangements, related-party relationships, or transactions requiring additional regulatory disclosure.

Also effective March 13, 2026, the board named Austin Charette, Agenus’ Senior Director of Financial Reporting and Compliance, as MiNK’s Principal Accounting Officer, tasking him with external reporting, technical accounting, internal controls, and implementation of new accounting standards for the company. Charette, who previously worked in Deloitte & Touche LLP’s audit and assurance practice, likewise serves MiNK solely through the intercompany services agreement with Agenus without direct compensation, underscoring MiNK’s strategy of leveraging Agenus’ finance infrastructure while maintaining regulatory clarity on governance and independence.

The most recent analyst rating on (INKT) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on MiNK Therapeutics stock, see the INKT Stock Forecast page.

Spark’s Take on INKT Stock

According to Spark, TipRanks’ AI Analyst, INKT is a Neutral.

The score is primarily held down by weak financial fundamentals (pre-revenue, negative equity, and highly concerning TTM cash flow metrics). This is partially offset by a constructive earnings call centered on clinical progress and runway, while technicals and valuation provide limited additional support.

To see Spark’s full report on INKT stock, click here.

More about MiNK Therapeutics

MiNK Therapeutics Inc. operates in the biotechnology and biopharmaceutical sector, focusing on developing innovative therapies, with corporate operations closely linked to Agenus Inc. through an intercompany services agreement. The company relies on shared financial and accounting infrastructure with Agenus, reflecting a lean operational model and an integrated approach to financial management and reporting.

Average Trading Volume: 291,533

Technical Sentiment Signal: Sell

Current Market Cap: $44.41M

For detailed information about INKT stock, go to TipRanks’ Stock Analysis page.